Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on March 10, 2021. The filing addresses a corporate action regarding the company's 6% Convertible Exchangeable Preferred Stock (CYCCP). Note: The request metadata lists "Bio Green Med Solution, Inc.", but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the dividend declaration:
- Dividend Amount: $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
- Record Date: April 16, 2021.
- Payment Date: May 1, 2021.
Material Changes
The filing reports the declaration of a quarterly cash dividend. The Board of Directors determined that the company had a requisite surplus to support this payment. No other material changes to operations or financial condition are detailed in this specific report.
Guidance, Outlook, and Risks
Management commentary indicates that while the Board considered financial analysis and surplus levels to declare this dividend, there is no assurance that future quarterly dividends will be declared. The Board will analyze the advisability of future declarations on a quarterly basis.
Investor Verification Checklist
- Verify the record date (April 16, 2021) to confirm eligibility for the $0.15 per share dividend.
- Confirm the payment date of May 1, 2021.
- Review the company's latest 10-Q or 10-K for full financial context, as this 8-K does not contain revenue or cash flow data.
- Note that future dividends are not guaranteed and depend on Board discretion and financial surplus.